Chinese General Practice ›› 2022, Vol. 25 ›› Issue (26): 3263-3269.DOI: 10.12114/j.issn.1007-9572.2022.0293
• Original Research • Previous Articles Next Articles
Received:
2022-02-14
Revised:
2022-06-19
Published:
2022-09-15
Online:
2022-07-06
Contact:
Ling YUAN
About author:
通讯作者:
袁翎
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0293
项目 | 总人群(n=44) | 基线LDH低水平者(n=28) | 基线LDH高水平者(n=16) | |
---|---|---|---|---|
年龄〔M(P25,P75),岁〕 | 64.5(57.0,69.8) | 63.0(55.2,68.8) | 67.0(57.0,72.0) | |
性别〔n(%)〕 | ||||
男 | 34(77.3) | 22(78.6) | 12(75.0) | |
女 | 10(22.7) | 6(21.4) | 4(25.0) | |
病变部位〔n(%)〕 | ||||
颈段+上段 | 6(13.6) | 4(14.3) | 2(12.5) | |
中下段 | 38(86.4) | 24(85.7) | 14(87.5) | |
有无吸烟史〔n(%)〕 | ||||
有 | 22(50.0) | 15(53.6) | 7(43.8) | |
无 | 22(50.0) | 13(46.4) | 9(56.2) | |
肿瘤分化程度〔n(%)〕 | ||||
高分化+中分化 | 30(68.2) | 21(75.0) | 9(56.2) | |
低分化 | 14(31.8) | 7(25.0) | 7(43.8) | |
既往行手术治疗〔n(%)〕 | ||||
有 | 10(22.7) | 7(25.0) | 3(18.8) | |
无 | 34(77.3) | 21(75.0) | 13(81.2) | |
既往放射治疗 | ||||
有 | 29(65.9) | 18(64.3) | 11(68.8) | |
无 | 15(34.1) | 10(35.7) | 5(31.2) | |
转移累及器官数〔n(%)〕 | ||||
≤2个 | 36(81.8) | 24(85.7) | 12(75.0) | |
≥3个 | 8(18.2) | 4(14.3) | 4(25.0) | |
基线LDH水平〔M(P25,P75),U/L〕 | 190.0(158.5,237.0) | 177.0(136.0,188.2) | 273.0(217.0,328.0) | |
血清白蛋白〔M(P25,P75),g/L〕 | 40.00(36.20,43.10) | 41.00(37.40,44.10) | 39.00(35.75,40.05) | |
血红蛋白〔M(P25,P75),g/L〕 | 122.0(105.0,140.0) | 120.5(106.0,137.8) | 122.0(104.0,143.0) | |
淋巴细胞计数〔M(P25,P75),×109/L〕 | 1.01(0.71,1.44) | 0.98(0.65,1.36) | 1.09(0.95,1.91) | |
单核细胞计数〔M(P25,P75),×109/L〕 | 0.27(0.18,0.34) | 0.26(0.15,0.34) | 0.31(0.22,0.43) |
Table 1 Baseline characteristics analysis of ESCC participants after immunotherapy on the whole and by baseline LDH level
项目 | 总人群(n=44) | 基线LDH低水平者(n=28) | 基线LDH高水平者(n=16) | |
---|---|---|---|---|
年龄〔M(P25,P75),岁〕 | 64.5(57.0,69.8) | 63.0(55.2,68.8) | 67.0(57.0,72.0) | |
性别〔n(%)〕 | ||||
男 | 34(77.3) | 22(78.6) | 12(75.0) | |
女 | 10(22.7) | 6(21.4) | 4(25.0) | |
病变部位〔n(%)〕 | ||||
颈段+上段 | 6(13.6) | 4(14.3) | 2(12.5) | |
中下段 | 38(86.4) | 24(85.7) | 14(87.5) | |
有无吸烟史〔n(%)〕 | ||||
有 | 22(50.0) | 15(53.6) | 7(43.8) | |
无 | 22(50.0) | 13(46.4) | 9(56.2) | |
肿瘤分化程度〔n(%)〕 | ||||
高分化+中分化 | 30(68.2) | 21(75.0) | 9(56.2) | |
低分化 | 14(31.8) | 7(25.0) | 7(43.8) | |
既往行手术治疗〔n(%)〕 | ||||
有 | 10(22.7) | 7(25.0) | 3(18.8) | |
无 | 34(77.3) | 21(75.0) | 13(81.2) | |
既往放射治疗 | ||||
有 | 29(65.9) | 18(64.3) | 11(68.8) | |
无 | 15(34.1) | 10(35.7) | 5(31.2) | |
转移累及器官数〔n(%)〕 | ||||
≤2个 | 36(81.8) | 24(85.7) | 12(75.0) | |
≥3个 | 8(18.2) | 4(14.3) | 4(25.0) | |
基线LDH水平〔M(P25,P75),U/L〕 | 190.0(158.5,237.0) | 177.0(136.0,188.2) | 273.0(217.0,328.0) | |
血清白蛋白〔M(P25,P75),g/L〕 | 40.00(36.20,43.10) | 41.00(37.40,44.10) | 39.00(35.75,40.05) | |
血红蛋白〔M(P25,P75),g/L〕 | 122.0(105.0,140.0) | 120.5(106.0,137.8) | 122.0(104.0,143.0) | |
淋巴细胞计数〔M(P25,P75),×109/L〕 | 1.01(0.71,1.44) | 0.98(0.65,1.36) | 1.09(0.95,1.91) | |
单核细胞计数〔M(P25,P75),×109/L〕 | 0.27(0.18,0.34) | 0.26(0.15,0.34) | 0.31(0.22,0.43) |
分类 | 例数 | ORR | SD | PD |
---|---|---|---|---|
基线LDH低水平者 | 28 | 16(57.2) | 10(35.7) | 2(7.1) |
基线LDH高水平者 | 16 | 3(18.8) | 7(43.7) | 6(37.5) |
Table 2 Prognosis of ESCC patients with low and high baseline LDH levels
分类 | 例数 | ORR | SD | PD |
---|---|---|---|---|
基线LDH低水平者 | 28 | 16(57.2) | 10(35.7) | 2(7.1) |
基线LDH高水平者 | 16 | 3(18.8) | 7(43.7) | 6(37.5) |
变量 | 赋值 |
---|---|
年龄 | 实测值 |
性别 | 男=0,女=1 |
病变部位 | 颈段+上段=0,中下段=1 |
有无吸烟史 | 无=0,有=1 |
肿瘤分化程度 | 低分化=0,高分化+中分化=1 |
既往行手术治疗 | 无=0,有=1 |
既往放射治疗 | 无=0,有=1 |
转移累及器官数 | ≤2个=0,≥3个=1 |
基线LDH水平 | <200 U/L=0,≥200 U/L=1 |
血清白蛋白 | <40 g/L=0,≥40 g/L=1 |
血红蛋白 | <130 g/L=0,≥130 g/L=1 |
淋巴细胞计数 | <1.39×109/L=0,≥1.39×109/L=1 |
单核细胞计数 | <0.39×109/L=0,≥0.39×109/L=1 |
Table 3 Variable assignment for potential factors associated with prognosis in patients with advanced ESCC after immunotherapy analyzed using univariate and multivariate Cox regression
变量 | 赋值 |
---|---|
年龄 | 实测值 |
性别 | 男=0,女=1 |
病变部位 | 颈段+上段=0,中下段=1 |
有无吸烟史 | 无=0,有=1 |
肿瘤分化程度 | 低分化=0,高分化+中分化=1 |
既往行手术治疗 | 无=0,有=1 |
既往放射治疗 | 无=0,有=1 |
转移累及器官数 | ≤2个=0,≥3个=1 |
基线LDH水平 | <200 U/L=0,≥200 U/L=1 |
血清白蛋白 | <40 g/L=0,≥40 g/L=1 |
血红蛋白 | <130 g/L=0,≥130 g/L=1 |
淋巴细胞计数 | <1.39×109/L=0,≥1.39×109/L=1 |
单核细胞计数 | <0.39×109/L=0,≥0.39×109/L=1 |
项目 | PFS | OS | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
B | SE | Wald χ2值 | P值 | HR(95%CI) | B | SE | Wald χ2值 | P值 | HR(95%CI) | |
年龄 | 0.002 | 0.018 | 0.018 | 0.894 | 1.002(0.967,1.039) | 0.002 | 0.020 | 0.006 | 0.937 | 1.002(0.962,1.043) |
性别 | -0.226 | 0.398 | 0.322 | 0.570 | 0.798(0.365,1.741) | 0.422 | 0.412 | 1.049 | 0.306 | 1.524(0.680,3.416) |
病变部位 | -0.687 | 0.624 | 1.210 | 0.271 | 0.503(0.148,1.711) | -1.023 | 0.567 | 3.248 | 0.072 | 0.360(0.118,1.094) |
有无吸烟史 | 0.292 | 0.328 | 0.793 | 0.373 | 1.339(0.704,2.545) | 0.241 | 0.360 | 0.449 | 0.503 | 1.272(0.629,2.575) |
肿瘤分化程度 | -0.340 | 0.352 | 0.935 | 0.334 | 0.711(0.357,1.419) | -0.560 | 0.385 | 2.113 | 0.146 | 0.571(0.268,1.215) |
既往行手术治疗 | 0.151 | 0.352 | 0.185 | 0.667 | 1.164(0.583,2.321) | 0.493 | 0.392 | 1.577 | 0.209 | 1.637(0.759,3.531) |
既往放射治疗 | 0.472 | 0.353 | 1.784 | 0.182 | 1.603(0.802,3.205) | 0.512 | 0.398 | 1.660 | 0.198 | 1.669(0.766,3.638) |
转移累及器官数 | 0.502 | 0.493 | 1.035 | 0.309 | 1.651(0.628,4.341) | 0.418 | 0.544 | 0.592 | 0.442 | 1.519(0.524,4.408) |
基线LDH | 0.884 | 0.367 | 5.794 | 0.016 | 2.420(1.178,4.971) | 1.291 | 0.407 | 10.070 | 0.004 | 3.637(1.638,8.074) |
血清白蛋白 | 0.714 | 0.453 | 2.480 | 0.115 | 2.042(0.840,4.964) | 0.398 | 0.491 | 0.658 | 0.417 | 1.489(0.569,3.898) |
血红蛋白 | -0.241 | 0.364 | 0.439 | 0.508 | 0.786(0.385,1.604) | -0.453 | 0.409 | 1.231 | 0.267 | 0.636(0.285,1.415) |
淋巴细胞计数 | -0.014 | 0.374 | 0.001 | 0.970 | 0.989(0.511,1.913) | -0.493 | 0.436 | 1.278 | 0.258 | 0.611(0.260,1.436) |
单核细胞计数 | -0.011 | 0.337 | 0.001 | 0.973 | 0.989(0.511,1.915) | -0.523 | 0.362 | 2.084 | 0.149 | 0.593(0.291,1.206) |
Table 4 Univariate Cox regression analysis of influencing factors of progression-free survival and overall survival in patients with advanced ESCC after immunotherapy
项目 | PFS | OS | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
B | SE | Wald χ2值 | P值 | HR(95%CI) | B | SE | Wald χ2值 | P值 | HR(95%CI) | |
年龄 | 0.002 | 0.018 | 0.018 | 0.894 | 1.002(0.967,1.039) | 0.002 | 0.020 | 0.006 | 0.937 | 1.002(0.962,1.043) |
性别 | -0.226 | 0.398 | 0.322 | 0.570 | 0.798(0.365,1.741) | 0.422 | 0.412 | 1.049 | 0.306 | 1.524(0.680,3.416) |
病变部位 | -0.687 | 0.624 | 1.210 | 0.271 | 0.503(0.148,1.711) | -1.023 | 0.567 | 3.248 | 0.072 | 0.360(0.118,1.094) |
有无吸烟史 | 0.292 | 0.328 | 0.793 | 0.373 | 1.339(0.704,2.545) | 0.241 | 0.360 | 0.449 | 0.503 | 1.272(0.629,2.575) |
肿瘤分化程度 | -0.340 | 0.352 | 0.935 | 0.334 | 0.711(0.357,1.419) | -0.560 | 0.385 | 2.113 | 0.146 | 0.571(0.268,1.215) |
既往行手术治疗 | 0.151 | 0.352 | 0.185 | 0.667 | 1.164(0.583,2.321) | 0.493 | 0.392 | 1.577 | 0.209 | 1.637(0.759,3.531) |
既往放射治疗 | 0.472 | 0.353 | 1.784 | 0.182 | 1.603(0.802,3.205) | 0.512 | 0.398 | 1.660 | 0.198 | 1.669(0.766,3.638) |
转移累及器官数 | 0.502 | 0.493 | 1.035 | 0.309 | 1.651(0.628,4.341) | 0.418 | 0.544 | 0.592 | 0.442 | 1.519(0.524,4.408) |
基线LDH | 0.884 | 0.367 | 5.794 | 0.016 | 2.420(1.178,4.971) | 1.291 | 0.407 | 10.070 | 0.004 | 3.637(1.638,8.074) |
血清白蛋白 | 0.714 | 0.453 | 2.480 | 0.115 | 2.042(0.840,4.964) | 0.398 | 0.491 | 0.658 | 0.417 | 1.489(0.569,3.898) |
血红蛋白 | -0.241 | 0.364 | 0.439 | 0.508 | 0.786(0.385,1.604) | -0.453 | 0.409 | 1.231 | 0.267 | 0.636(0.285,1.415) |
淋巴细胞计数 | -0.014 | 0.374 | 0.001 | 0.970 | 0.989(0.511,1.913) | -0.493 | 0.436 | 1.278 | 0.258 | 0.611(0.260,1.436) |
单核细胞计数 | -0.011 | 0.337 | 0.001 | 0.973 | 0.989(0.511,1.915) | -0.523 | 0.362 | 2.084 | 0.149 | 0.593(0.291,1.206) |
项目 | B | SE | Wald χ2值 | P值 | HR(95%CI) |
---|---|---|---|---|---|
基线LDH | 2.859 | 1.044 | 7.498 | 0.001 | 17.440(2.254,134.962) |
血红蛋白 | -5.321 | 1.633 | 10.614 | 0.001 | 0.005(<0.001,0.120) |
单核细胞计数 | -2.713 | 1.056 | 6.604 | 0.010 | 0.066(0.008,0.525) |
Table 5 Multivariate Cox regression analysis of influencing factors of overall survivalin patients with advanced ESCC after immunotherapy
项目 | B | SE | Wald χ2值 | P值 | HR(95%CI) |
---|---|---|---|---|---|
基线LDH | 2.859 | 1.044 | 7.498 | 0.001 | 17.440(2.254,134.962) |
血红蛋白 | -5.321 | 1.633 | 10.614 | 0.001 | 0.005(<0.001,0.120) |
单核细胞计数 | -2.713 | 1.056 | 6.604 | 0.010 | 0.066(0.008,0.525) |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
麦海强,莫浩元,洪明晃,等. 鼻咽癌放疗前血红蛋白浓度对局部控制的影响[J]. 癌症,2005,24(6):727-730. DOI:10.3321/j.issn:1000-467X.2005.06.020.
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[38] |
|
[39] |
|
[40] |
|
[41] |
|
[42] |
|
[1] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[2] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[3] | ZHANG Jifang, CHEN Fang, TANG Jiawen, LI Hongliang. Predictive Value of Tumor Budding and Tumor-infiltrating Lymphocytes on Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(32): 4038-4042. |
[4] | MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102. |
[5] | ZHANG Ming, XU Jing, SUN Zhenhua, ZHAO Wenhao, MA Yingqian, ZHANG Jianqiao, SHEN Haiping. Improvement of Nutritional Status of Elderly Patients with Severe Obstruction Esophageal Carcinoma by Image-guided Photodynamic Therapy [J]. Chinese General Practice, 2023, 26(30): 3780-3784. |
[6] | SHI Xiaoqi, LUO Nandu, HUANG Jiaojiao, DU Zuochen, HUANG Pei, CAO Xiuli, CHEN Yan, HE Zhixu. Correlation between Aspartate Aminotransferase/Alanine Aminotransferase and Prognosis of Hemophagocytic Lymphohistiocytosis in Children [J]. Chinese General Practice, 2023, 26(30): 3801-3808. |
[7] | LI Jilei, LI Honglin, XU Yanchao, LIU Yanan, CHEN Mengli, SHAO Shuai, MA Chunzheng. Clinical Study on the Combination of Xiaotan Huayu Tongyi Granules, Channel Kaijie Pills and Chemotherapy in the Treatment of Esophageal Cancer [J]. Chinese General Practice, 2023, 26(30): 3759-3764. |
[8] | ZHENG Yuling, ZHANG Yaling, LIU Huaimin, XU Yanchao, JIA Xiaolin, LI Junsai, HE Wenlong, TONG Xinduo, QIN Shanwen, ZHANG Lihan. Clinical Observation of Dingxiang Guanshitong Hanhua Pills Alone and Its Combination with Fugui Guanshitong Granules in the Treatment of Advanced Esophageal Cancer [J]. Chinese General Practice, 2023, 26(30): 3765-3771. |
[9] | YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779. |
[10] | YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790. |
[11] | TANG Shilan, XIE Kexin, LIU Lingyu, QI Tiantian, YANG Yansui. Advances in Rehabilitation Outcomes and Care in Patients with Prolonged Disorders of Consciousness [J]. Chinese General Practice, 2023, 26(27): 3342-3348. |
[12] | SUN Shuaigang, SHENG Xiaoxiao, ZHANG Wenhui, TIAN Huijuan, ZHAI Yaling. The Analysis of Clinicopathological Characters and Short-term Prognosis in Idiopathic Membranous Nephropathy Patients with Immunoglobulin G4 Combined with Other Different Immunoglobulin G Subtypes Deposition [J]. Chinese General Practice, 2023, 26(21): 2632-2638. |
[13] | XUE Shan, LI Laiyou, LIANG Junli, JIN Yinghui, WEI Shuyan. The Efficacy and Safety of Home Enteral Nutrition in Patients with Esophageal Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(20): 2540-2547. |
[14] | ZHANG Yushuang, KONG Lingyang, GUAN Jiachang, LI Jianbo, WANG Yiran, WANG Yu, LI Jing. 16S rDNA Sequence Analysis of the Characteristics of Gut Flora in Patients with Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(20): 2496-2502. |
[15] | ZHAO Zewei, KANG Ning, GUO Fengli, WANG Zhongyu, ZHENG Xiangqian. Effect of Aurora Kinase A Expression on Biochemical Cure in Patients after Medullary Thyroid Cancer Resection [J]. Chinese General Practice, 2023, 26(20): 2508-2512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||